| INTRODUC TI ON
The levels of sex steroids decline progressively in men throughout adult life, and their relationship with health during ageing is likely to be complex. 1 Testosterone is the main sex steroid hormone in men and the most investigated in relation to health outcomes. Oestradiol, considered for a long time as the female hormone, is mainly synthesized in men from testosterone via adipose aromatase, 2 but has not been widely investigated in this population. Although its concentration in men is about 200 times lower than that of testosterone, it is higher than the concentration in postmenopausal women and comparable to oestradiol levels found in women in the early follicular phase of the menstrual cycle. 3 In addition, it has been suggested that oestradiol could play a crucial role in a number of physiologic functions in men, including regulation of body fat and sexual function, 4 bone metabolism, 5, 6 brain functioning, 7 and regulation of testosterone biosynthesis and spermatogenesis. 8 In women, there is some evidence that high levels of endogenous oestradiol may be associated with increased mortality. 9, 10 Few studies have examined this question in men, with inconsistent findings. While some studies showed no association, [11] [12] [13] [14] other studies found significant associations but in opposite directions. [15] [16] [17] [18] In addition, most studies focused on all-cause mortality, and cause-specific mortality has been little investigated.
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Oestrogens mainly act through two distinct types of oestrogen
receptors (ER), ERα encoded by the ESR1 gene and ERβ encoded
by the ESR2 gene. 20, 21 Functional genetic polymorphisms have been identified in both genes that could modify ER transcription and may influence the occurrence of different health outcomes in both men and women. [22] [23] [24] In women, ER genetic polymorphisms modify the association of endogenous oestradiol with breast cancer and ischaemic arterial disease. 25, 26 In men, the association of ER genetic polymorphisms with Alzheimer disease, cardiovascular disease (CVD) and cancer has been examined, [27] [28] [29] but no studies investigated the interaction between ER genetic polymorphisms and oestradiol on mortality risk. Such an interaction, if confirmed, could account for inconsistent results of previous studies.
We used data from the French Three-City (3C) prospective cohort study to investigate the relationship of oestradiol levels with all-cause and cause-specific mortality in men after 65 years and to examine whether ER genetic polymorphisms modify the relation with all-cause mortality.
| SUBJEC TS AND ME THODS

| Study population
The subjects included in the present analysis consist of a subsample of the 3C study, a large ongoing French prospective cohort study on the relationship between vascular risk factors and dementia. The study protocol was approved by the Ethics Committee of the University Hospital of Kremlin-Bicêtre, and a written informed consent was obtained from all participants.
The detailed protocol is available elsewhere. 30 Briefly, 9294 noninstitutionalized subjects (3650 men, 5644 women) aged at least 65 years were selected from the electoral rolls of three 
| Assessment of mortality over the follow-up
After the baseline examination, participants were assessed 5 times every 2 to 3 years. 
| Hormones and steroid-bound proteins measurement
Total oestradiol (tE2), total testosterone, sex hormone-binding globulin (SHBG) and albumin were measured in a random subsample of the original cohort. The subcohort was selected within participants with a blood sample, after stratification by sex, centre and age. Our analyses are therefore based on men from the subcohort, after ex- EDTA plasmas were obtained after one centrifugation at 3000 g and were immediately stored at −80°C in 1 mL plastic tubes.
Plasma tE2 was measured by a sensitive direct radioimmunoassay (RIA) with an Orion Diagnostica device (Spectria, Espoo, Finland).
The minimum detectable concentration was 2 pg/mL (7.3 pmol/L).
The intra-assay and inter-assay coefficients of variation were 17.6% and 18.1%, respectively, for a tE2 concentration of 3.2 pg/mL (12 pmol/L) and were 2.8% and 5.8%, respectively, for a tE2 concentration of 24 pg/mL (88.1 pmol/L).
Total testosterone was also measured by a direct RIA as previ- 
| Covariates
| Statistical analysis
The baseline characteristics of the study population were expressed as means ± standard deviation (SD) for normally distributed con- Hazard ratios (HRs) and 95% confidence intervals (95% CI) were estimated with Cox proportional hazards models and age as the time scale, for all-cause and cause-specific mortality. 35 For all-cause mortality, participants were followed-up until death from any cause or the date of censoring (date of last news alive); for cause-specific mortality, participants were followed-up until death from a specific cause or the date of censoring (death of another cause, date of last news alive). Schoenfeld residuals and log-minus-log-plots were examined to confirm the proportional hazards assumption. No major violations were observed in any model.
To model the association between oestradiol (tE2, fE2) and mortality, we categorized oestradiol level into tertiles; as there was evidence in favour of a nonlinear relation with all-cause mortality, we used the middle tertile as the reference group, and tested for a quadratic association using orthogonal polynomial contrasts. We then used multivariate restricted cubic spline (RCS) with three knots placed at the 10th, 50th and 90th percentiles of the oestradiol distribution to provide a graphical presentation when the quadratic association was verified in tertiles analysis. 36 Splines allowed us to test whether there was a significant departure from a linear association;
if yes, we tested the overall effect of the spline transformations.
Three models are presented: the first model was adjusted for age (time scale) and centre; the second was further adjusted for variables associated either with mortality or oestradiol level at P ≤ 0.10 (personal history of coronary disease and stroke, daily alcohol consumption, hypertension, diabetes, SHBG); the final model was further adjusted for other traditional risk factors (smoking status, BMI, hypercholesterolemia). For these analyses, we created extra categories for covariates with missing values to keep the same number of subjects in the analyses. For each variable included in the models, the interaction with oestradiol level on all-cause and cause-specific mortality was tested. None was significant.
We tested multiplicative interactions between each ESR1 and ESR2 SNP and tertiles of oestradiol on the risk of all-cause mortality under codominant and additive models. We used a Bonferroni correction to account for multiple testing: interactions were considered significant at P ≤ 0.005 (0.05 divided by 5 × 2, corresponding to the number of SNPs and genetic models examined).
We did not investigate interactions between SNPs and oestradiol on cause-specific mortality due to an insufficient number of events.
Analyses were weighted using stabilized inverse probability weighting (IPW) to take into account the fact that oestradiol was measured in a random subcohort. 37 Weights were calculated for each individual based on data on all 3,650 men from the cohort. The probability of being included in the subcohort was estimated based on sociodemographic characteristics (age, education, height, occupational position, marital status), health behaviours (smoking, alcohol consumption, fruit and vegetable consumption), cardiometabolic risk factors (BMI, hypertension, diabetes, cholesterol), chronic conditions (coronary heart disease, stroke) and cognitive function (Mini Mental Scale scores) from study baseline and mortality until the end of follow-up.
Different sensitivity analyses were performed as described below. First, we estimated the risk of all-cause and cause-specific mortality in relation to oestradiol after exclusion of participants who died during the first four years of follow-up. Second, to examine whether the association of oestradiol with mortality could partly reflect the role of testosterone, we further adjusted model 3
for this hormone (model 4, Data S1); in this model, we also included significant interactions of testosterone with diabetes and hypertension. Finally, we used a case-only design to assess the interaction between oestrogen receptor polymorphism and oestradiol; under the assumption that both factors are independent in controls, this approach allows to increase statistical power. 38 We examined associations between oestrogen receptor polymorphism and tertiles of oestradiol among cases (men who died during the 12 year follow-up) and controls (those who remained alive) using the chi-square test.
Statistical analyses were performed using SAS 9.4 (SAS Institute, Inc., Cary, NC, USA). Figure 1 shows the selection of the study sample. The subcohort of 495 men represents a random subsample of all men (n = 3650); men included in the subcohort were similar to the 3155 men not included, except for personal history of coronary heart disease and triglyceride levels (Table S1 (see Supporting Information)). To validate the random sampling and the adequacy of the IPW procedure, we compared the association of cardiometabolic risk factors (diabetes, hypertension) and medical history (coronary heart disease, stroke) with 12-year mortality in the overall cohort and in the sub-cohort (with and without IPW; Table S2 (see Supporting Information)). These results support the adequacy of the IPW procedure.
| RE SULTS
One man from the subcohort without oestradiol data and 22 men who used treatments that might change oestradiol levels were excluded. They did not differ from the others in terms of age, Ta b l e 1 . Baseline characteristics of men according to the vital status after a 12-year follow-up in the 3C cohort study socio-demographic characteristics and risk factors. The remaining 472 subjects constitute the sample for our analysis (Figure 1 ). Their baseline characteristics are presented in Table 1 .
Over 12 years of follow-up, 183 men died (38.8%); 44 died from CVD, 57 from cancer and 82 from others causes. Compared to survivors, those who died were significantly older at baseline (Table 1) ; after adjustment for age, they were also more likely than others to be current daily alcohol drinkers and diabetic and to have a personal history of stroke. Overall, mean concentrations of tE2 and fE2 were 19.8 pg/mL and 0.7 pg/mL, respectively. Mean tE2 tended to be higher in those who died compared to those who remained alive, and the difference was statistically significant for fE2.
There was a strong positive correlation between tE2 and fE2
(r = 0.99; P < 0.001); we therefore report here results for tE2 and provide those for fE2 in Material S1 (see Supporting Information). Data are expressed as n (%), means (SD), or medians (IQR). %, percentage; BMI, body mass index; fE2, free oestradiol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; n, Numbers; SD, Standard deviation; SHBG, Sex Hormone-Binding Globulin; T, tertile of total oestradiol (cut-off in pg/mL). Missing data: The baseline characteristics of participants according to tertiles of tE2 are presented in Table 2 (Table S3 in the Supporting Information for fE2). Clinical and biological characteristics did not differ according to tertiles of tE2, except for hypertension whose prevalence significantly increased with oestradiol level.
Associations of baseline endogenous tE2 level with all-cause and
cause-specific mortality are presented in Table 3 and Figure 2 . There was a significant quadratic relation (model 3, P-quadratic = 0.04) between tE2 and all-cause mortality, with a higher hazard of death for participants in the bottom and top tertiles compared to those in the middle one; analyses using splines confirmed that there was a significant departure from a linear association (P < 0.01) and the graphical representation of the relation is consistent with a quadratic relation. The association between tE2 and all-cause mortality was significant for the top tertile (model 3, P = 0.05); it was not significant for the bottom tertile (model 3, P = 0.12), but there was no significant difference between the top and bottom tertiles (model
This pattern depended on the cause of death (Pheterogeneity < 0.05). The quadratic association was even more pronounced for CVD mortality (model 3, P-quadratic = 0.01, Pdeparture from linearity = 0.05), with a strong association for the top tertile compared to the middle one (model 3, HR = 3.50, 95% CI = 1.55-7.90, P < 0.01); the association was not significant for the bottom tertile (model 3, HR = 2.05, 95% CI = 0.86-4.89, P = 0.10), but there was no significant difference between the top and bottom tertiles (model 3, P = 0.21). There was no significant association of tE2 level with cancer mortality and other cause of mortality.
Analysis based on fE2 lead to similar conclusions (Table S4 , and Figure S1 for fE2 found in the Supporting Information).
The genotypic frequencies of the SNPs were in Hardy-Weinberg equilibrium. They were associated neither with mortality nor with oestradiol level (Tables S5-S6 (see Supporting Information)). Table 4 shows the association between tertiles of tE2 and all-cause mortality stratified by the genotypes (Table S7 for fE2 (see Supporting Information)). There were no significant interactions between tE2
and none of the SNPs on all cause-mortality.
In sensitivity analyses, we excluded participants who died during the first four years of follow-up (n = 41) and found very similar findings (Table S8 ( unchanged in models adjusted for testosterone (Table S9 ( (Tables S10 and S11 for tE2 and fE2, respectively in the Supporting Information).
| D ISCUSS I ON
As part of the 3C prospective cohort study in aging men, we showed a quadratic association between the baseline concentration of endogenous oestradiol (tE2 and fE2) and all-cause mortality over a 12-year follow-up that was independent of age, personal history of coronary disease and stroke, daily alcohol consumption, hypertension, diabetes, smoking, BMI, hypercholesterolemia and SHBG. This pattern was explained by CVD mortality, while there was no association with cancer mortality. There was no evidence of interactions between SNPs in ER genes and endogenous oestradiol for all-cause mortality.
To our knowledge, our study is the first to show a significant quadratic association of oestradiol with all-cause mortality among elderly men from the general population. They are, however, in line with an association of low and high oestradiol level, compared to middle values, with increased all-cause mortality among men with chronic heart failure. 39 Other studies reported that either low oestradiol levels, 16, 19 or high oestradiol levels 15, 17 were associated with increased mortality. There are also studies showing no association between endogenous oestradiol and all-cause mortality.
11-14
Possible explanations for these inconsistencies might be differences in subjects' characteristics, numbers of events and adjustment for different covariates. Negative results tended to be more frequently observed in studies based on middle-aged men 11, 12, 14 ; biological effects of oestradiol might be more prominent in older men, or low mortality rates in middle-aged men may have led to insufficient statistical power.
The quadratic association of oestradiol with mortality was stronger for CVD mortality. Current knowledge on the relation between endogenous oestradiol and cardiovascular risk in men is limited and controversial. Some studies reported no association of endogenous oestradiol with CVD mortality, 11, 12, 17 but one recent study showed that lower oestradiol levels were associated with increased CVD mortality. 19 With respect to incident CVD, one meta-analysis showed no conclusive results on the relation between endogenous oestradiol and CVD risk among men. 40 In the Framingham Heart Study, low oestradiol levels were associated with an increased risk of atrial fibrillation. 19, 41 Another prospective study showed that high levels of endogenous oestradiol levels predicted incident stroke.
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We found no association of oestradiol with cancer mortality, in agreement with previous studies. 11, 43, 44 We cannot exclude that associations may exist for specific cancers, but there were too few cases to perform cancer-specific analysis.
Previous studies have examined marginal associations between ER SNPs and several outcomes in men, and some reported significant associations with Alzheimer's disease, prostate cancer, chronic hepatitis B and CVD. 25, 27, 45, 46 However, no previous study examined whether ER SNPs modified the association of endogenous oestradiol with clinical outcomes or death and we found no evidence in favour of this hypothesis. Our study may suffer from insufficient statistical power; however, our findings were confirmed using a caseonly approach that is more powerful to detect gene-environment interactions than a traditional analysis.
Several biological mechanisms could explain the association of endogenous oestradiol with CVD mortality. First, high or low endogenous oestradiol could be associated with a worse profile of traditional cardiovascular risk factors, including obesity, diabetes and hypercholesterolemia. In our analysis, adjustment for diabetes for obesity, as BMI may not be the best way to capture fat mass.
Second, the relationship between oestradiol and CVD mortality could be driven by other mechanisms involved in atherothrombosis, such as inflammation and hypercoagulability. Additional data would be needed to examine whether these mechanisms mediate the association between oestradiol and mortality. Third, since oestradiol and testosterone levels are correlated, association of oestradiol with mortality may partly reflect the role of testosterone.
47
Indeed, both low and high testosterone levels may be associated with mortality in older men. 13 In our study, the correlation between tE2 and testosterone was r = 0.35; P < 0.0001. However, further adjustment for testosterone did not change the results. Finally, reverse causation could explain the increased risk of death for the low or high oestradiol levels. However, exclusion of deaths occurring during the first four years of follow-up yielded similar results and does not support this hypothesis.
Our study presents several strengths. We used data from a large multicenter population-based prospective French cohort study with a long-follow-up. Sensitivity analyses confirmed our main findings and suggest that the associations that we identified are robust.
Oestradiol measurements were conducted without knowledge of vital status and with an ultrasensitive method that yielded no values under the detectable concentrations.
Our study also has limitations. First, our analyses are based on a random stratified subcohort of men, rather than on the whole cohort.
Ta b l e 4 . All-cause mortality according to baseline total oestradiol concentration by ER Polymorphisms in the 3C cohort study We used IPW to take into account the sampling of the subcohort and to correct for the small differences observed between men from the subcohort and other men. Therefore, although this approach led to less precise estimates (compared to using the whole cohort), the random sampling is unlikely to lead to biased estimates. Nevertheless, the reduced sample may have led to insufficient power for some analyses, especially for analyses of gene-environment interactions.
Second, oestradiol measurement was measured using RIA rather than by the state-of-the-art gas chromatography mass spectrometry method. 48 A validation study compared values of tE2 measured by gas chromatography-tandem mass spectrometry and those obtained by the specific direct RIA used in our study and showed an excellent correlation between both methods for ranges of concentrations similar to those we observed (r = 0.969; P < 0.0001). 49 Therefore, use of this ultrasensitive direct RIA is adequate for oestradiol assessment in large epidemiological investigations in which population level inferences are of greater interest than subject-specific ones. In addition, residual error measurement for the RIA method would lead to underestimate true associations. Third, our analyses are based on a single measurement of oestradiol that does not take into account within-subject variability of sex hormones. However, blood samples were all collected in the morning from fasting men and there is no diurnal variation for oestradiol, especially in elderly men. 50 Finally, this study is based on older men, and, therefore, our findings may not be generalized to men younger than 65 years.
| CON CLUS ION
In conclusion, we identified a quadratic association between tE2, fE2 level and all-cause mortality that seemed to be not modified by SNPs in ER genes. These quadratic associations were explained by CVD deaths and did not exist for cancer mortality. These results could help improve our understanding of the role of oestradiol in men's health. The mechanisms underlying these associations remain to be elucidated.
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